Milestones

2022

Needle-free Injection has been accepted by Chinese Medical Insurance. Establish cooperation with Medicine Manufacturer to study vaccine injection.

2021

Launched QS-K in Chinese Market.

2019

Finished clinical study and published on Lancet, this was the first clinical trial related to NFIs in the world involved in over 400 diabetic patients.

2018

Launched QS-P in Chinese market. QS-K was developed and gained Reddot Design Award.

2017

Gained CE & ISO on QS-M & QS-P, CFDA on QS-P.

2015

QS-M gained Reddot Design Award and Red Star Design Award.

2014

QS Medical was approved as Chinese High-tech Enterprise, QS-P was developed.

2012

QS-M achieved CFDA approval.

2007

QS Medical transition to Quinovare, QS-M was developed.

2005

Needle-free injector research center was set up.